Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:ANL NASDAQ:GNTA OTCMKTS:IMUC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.98+2.1%$2.10$1.33▼$3.16$93.32M0.7490,562 shs38,716 shsANLAdlai Nortye$1.72-3.1%$1.68$1.10▼$3.89$63.84M-0.8713,160 shs2,213 shsGNTAGenenta Science$3.24-2.3%$3.43$2.56▼$7.28$60.36M0.5814,242 shs6,864 shsIMUCEOM Pharmaceutical$0.08-3.6%$0.08$0.01▼$0.21$9.60M0.053,062 shs2,797 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%+1.02%-7.48%+5.04%-16.81%ANLAdlai Nortye0.00%-0.58%-2.27%+9.83%-13.13%GNTAGenenta Science0.00%+4.15%-7.57%-16.39%-27.63%IMUCEOM Pharmaceutical0.00%-5.13%+9.05%+6.75%-5.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.98+2.1%$2.10$1.33▼$3.16$93.32M0.7490,562 shs38,716 shsANLAdlai Nortye$1.72-3.1%$1.68$1.10▼$3.89$63.84M-0.8713,160 shs2,213 shsGNTAGenenta Science$3.24-2.3%$3.43$2.56▼$7.28$60.36M0.5814,242 shs6,864 shsIMUCEOM Pharmaceutical$0.08-3.6%$0.08$0.01▼$0.21$9.60M0.053,062 shs2,797 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%+1.02%-7.48%+5.04%-16.81%ANLAdlai Nortye0.00%-0.58%-2.27%+9.83%-13.13%GNTAGenenta Science0.00%+4.15%-7.57%-16.39%-27.63%IMUCEOM Pharmaceutical0.00%-5.13%+9.05%+6.75%-5.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 2.60Moderate Buy$7.00253.54% UpsideANLAdlai Nortye 1.50Reduce$9.00423.26% UpsideGNTAGenenta Science 1.00SellN/AN/AIMUCEOM Pharmaceutical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMUC, ADAG, GNTA, and ANL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025ADAGAdageneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ANLAdlai NortyeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell ➝ Sell (E+)9/27/2025GNTAGenenta ScienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/15/2025ADAGAdageneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.008/6/2025ADAGAdageneLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025ADAGAdageneLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$100K933.17N/AN/A$1.14 per share1.74ANLAdlai Nortye$5M12.69N/AN/A$0.69 per share2.49GNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$33.42MN/A0.00N/AN/AN/AN/AN/AN/AANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/AN/AGNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AIMUCEOM Pharmaceutical-$1.89MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/AANLAdlai NortyeN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdageneN/A2.29N/AANLAdlai NortyeN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%ANLAdlai Nortye35.21%GNTAGenenta Science15.13%IMUCEOM PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipADAGAdagene21.20%ANLAdlai NortyeN/AGNTAGenenta Science28.99%IMUCEOM Pharmaceutical3.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.13 million37.14 millionNot OptionableANLAdlai Nortye12736.90 millionN/ANot OptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableIMUCEOM Pharmaceutical3126.50 million122.35 millionNot OptionableIMUC, ADAG, GNTA, and ANL HeadlinesRecent News About These CompaniesQ32 Bio Inc. R (DB0.BE)January 15, 2025 | finance.yahoo.comImmunoCellular Therapeutics, Ltd. (IMUC)January 5, 2024 | uk.finance.yahoo.comEOM Pharmaceutical Holdings Inc.December 29, 2023 | wsj.comEOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613November 7, 2023 | finance.yahoo.comAAO 2023: Apellis unveils data from GALE extension studyNovember 4, 2023 | ophthalmologytimes.comOIZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 YearsNovember 4, 2023 | markets.businessinsider.comImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives RevenuesNovember 3, 2023 | msn.comOramed Pharmaceuticals Inc ORMPNovember 1, 2023 | morningstar.comMAnalyst Ratings for Olema PharmaceuticalsOctober 11, 2023 | markets.businessinsider.comEOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in BrazilSeptember 6, 2023 | finance.yahoo.comQ2 2023 PAVmed Inc Earnings CallAugust 17, 2023 | uk.finance.yahoo.comEOM Pharmaceuticals shelves plans to uplist shares, raise $15MAugust 3, 2023 | msn.comSYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over ...July 30, 2023 | bakersfield.comBAcumen Pharmaceuticals Announces Proposed Public Offering of Common StockJuly 17, 2023 | benzinga.comFDA rejects Amneal's Parkinson's drugJuly 5, 2023 | beckershospitalreview.comBAmneal Pharmaceuticals: FDA Requests Additional Information on IPX203 IngredientJuly 3, 2023 | marketwatch.comBishop Rehabilitation & Nursing Names Their June 2023 EOMJune 26, 2023 | patch.comAmneal Pharmaceuticals Gets FDA Approval for Injectable Tumor TreatmentJune 14, 2023 | marketwatch.comTrade commission fights Amgen's $28B purchase of Horizon TherapeuticsMay 16, 2023 | msn.comOramed: Q1 Earnings SnapshotMay 12, 2023 | timesunion.comTMedia Sentiment Over TimeIMUC, ADAG, GNTA, and ANL Company DescriptionsAdagene NASDAQ:ADAG$1.98 +0.04 (+2.06%) Closing price 10/3/2025 03:55 PM EasternExtended Trading$1.99 +0.01 (+0.56%) As of 10/3/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Adlai Nortye NASDAQ:ANL$1.72 -0.06 (-3.10%) Closing price 10/3/2025 03:55 PM EasternExtended Trading$1.72 0.00 (0.00%) As of 10/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Genenta Science NASDAQ:GNTA$3.24 -0.08 (-2.27%) As of 10/3/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.EOM Pharmaceutical OTCMKTS:IMUC$0.08 0.00 (-3.56%) As of 10/3/2025 11:11 AM EasternImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
